Thrombotic Thrombocytopenic Purpura (TTP) Market Report 2026

The thrombotic thrombocytopenic purpura (ttp) market size has grown steadily in recent years. It will grow from $1.04 billion in 2025 to $1.09 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to improved recognition of rare hematologic disorders, availability of plasma exchange therapy, increased survival rates due to early treatment, expansion of hospital-based intensive care services, development of rituximab-based treatments.

The thrombotic thrombocytopenic purpura (ttp) market size is expected to see steady growth in the next few years. It will grow to $1.29 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing adoption of caplacizumab therapy, rising investments in rare disease research, expansion of genetic testing for adamtS13 deficiency, growing focus on early relapse prevention, increasing establishment of specialized ttp treatment centers. Major trends in the forecast period include increasing use of targeted biologic therapies, rising adoption of plasma exchange innovations, growing focus on rapid diagnostic protocols, expansion of specialized treatment centers, enhanced patient monitoring technologies.

The rising prevalence of cardiovascular diseases is expected to drive the growth of the thrombotic thrombocytopenic purpura (TTP) market in the coming years. Cardiovascular diseases encompass a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. Factors contributing to the increasing prevalence of cardiovascular diseases include aging populations, unhealthy diets, physical inactivity, obesity, smoking, excessive alcohol consumption, and elevated stress levels. Thrombotic thrombocytopenic purpura (TTP) exacerbates cardiovascular conditions by causing widespread microvascular thrombosis, endothelial dysfunction, and systemic inflammation, which elevate the risk of hypertension, myocardial infarction, and other cardiovascular complications. For example, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000, up 4% from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular diseases is fueling growth in the TTP market.

The increase in healthcare spending is anticipated to further propel the thrombotic thrombocytopenic purpura (TTP) market. Healthcare spending refers to total expenditures on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, aimed at maintaining or improving population health. Factors driving higher healthcare spending include aging populations, medical technology advancements, rising chronic disease prevalence, and growing demand for healthcare services. Increased expenditure supports TTP management by enabling access to advanced diagnostics, life-saving treatments such as plasma exchange and immunosuppressive therapy, continuous patient monitoring, and research into innovative therapies, ultimately improving patient outcomes and reducing complications. For instance, in May 2024, the UK Office for National Statistics reported that between 2022 and 2023, healthcare spending in the UK increased by 5.6%, compared to 0.9% growth in 2022, totaling around $317.63 billion (£292 billion) in 2023. Therefore, rising healthcare spending is driving growth in the TTP market.

Key companies in the thrombotic thrombocytopenic purpura (TTP) market are focusing on developing innovative therapies, including recombinant enzyme replacement therapy, to improve treatment outcomes and patient care. Recombinant enzyme replacement therapy involves administering synthetic or bioengineered enzymes to patients with enzyme deficiency disorders to restore normal metabolic function. For example, in November 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, announced ADZYNMA, a recombinant ADAMTS13 enzyme replacement therapy approved by the U.S. Food and Drug Administration (FDA). ADZYNMA is the first and only therapy for congenital thrombotic thrombocytopenic purpura (cTTP) in both adults and pediatric patients. Congenital TTP is an ultra-rare blood clotting disorder caused by ADAMTS13 enzyme deficiency. Clinical trials demonstrated that ADZYNMA effectively reduces the risk of acute TTP events, and it is now available in the U.S. for both prophylactic and on-demand treatment.

Major companies operating in the thrombotic thrombocytopenic purpura (ttp) market are Pfizer Inc., Takeda Pharmaceutical Company, Sanofi S.A., Baxter International Inc., Octapharma AG, Omeros Corporation, Rigel Pharmaceuticals Inc., Biocryst Pharmaceuticals Inc., TargED Biopharmaceuticals B.V., Carelon Research, Archemix Corp., Eisai Inc., Shionogi & Co. Ltd., Global Blood Therapeutics, Beijing InnoCare Pharma, Gilead Sciences, Merck & Co. Inc., AstraZeneca, Janssen Pharmaceutical Companies, F Hoffmann‑La Roche Ltd, CSL Behring.

North America was the largest region in the thrombotic thrombocytopenic purpura (TTP) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thrombotic thrombocytopenic purpura (ttp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thrombotic thrombocytopenic purpura (ttp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the thrombotic thrombocytopenic purpura market by increasing costs of imported biologics, plasma exchange equipment, monoclonal antibodies, and specialized diagnostic tools. Treatment centers in North America and Europe are most affected due to reliance on high-cost imported therapies, while Asia-Pacific faces access challenges for advanced biologics. These tariffs are elevating treatment costs and affecting therapy availability. However, they are also encouraging domestic biologics manufacturing, regional plasma processing capacity, and localized supply chains for critical therapies.

The thrombotic thrombocytopenic purpura (ttp) market research report is one of a series of new reports that provides thrombotic thrombocytopenic purpura (ttp) market statistics, including thrombotic thrombocytopenic purpura (ttp) industry global market size, regional shares, competitors with a thrombotic thrombocytopenic purpura (ttp) market share, detailed thrombotic thrombocytopenic purpura (ttp) market segments, market trends and opportunities, and any further data you may need to thrive in the thrombotic thrombocytopenic purpura (ttp) industry. This thrombotic thrombocytopenic purpura (ttp) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially life-threatening blood disorder characterized by the formation of small blood clots (thrombi) in blood vessels throughout the body. These clots can obstruct blood flow to organs, potentially causing organ damage. TTP is primarily treated with plasmapheresis, which removes harmful antibodies and replaces the deficient ADAMTS13 enzyme.

The main types of thrombotic thrombocytopenic purpura (TTP) are inherited TTP and acquired TTP. Inherited TTP is a rare genetic disorder caused by mutations in the ADAMTS13 gene, resulting in defective breakdown of von Willebrand factor and recurrent episodes of blood clotting. Treatment options include plasma exchange, corticosteroids, rituximab, caplacizumab, and other therapies. These treatments are utilized by end-users such as hospitals, specialty centers, and other healthcare facilities.

The thrombotic thrombocytopenic purpura (TTP) market consists of revenues earned by entities by providing services such as diagnostic services, immunosuppressive therapy, hospitalization & intensive care services, patient support programs, long-term management and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombotic thrombocytopenic purpura (TTP) market also includes sales of immunosuppressants, plasma-based therapies, monoclonal antibodies, and supportive care treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.